SERPING1 and hereditary angioedema: Regular intravenous administration of C1-INH (Product B) [11] or subcutaneous administration of C1-INH (Product A) [12] has been shown to be effective, safe, and beneficial in minimizing HAE attacks and improving the quality of life also in children (Table 4).